Literature DB >> 19922537

Phe369(7.38) at human 5-HT(7) receptors confers interspecies selectivity to antagonists and partial agonists.

Thibault Varin1, Hugo Gutiérrez-de-Terán, Marián Castro, José Brea, Frederic Fabis, François Dauphin, Johan Aqvist, Alban Lepailleur, Pilar Perez, Javier Burgueño, José Miguel Vela, Maria Isabel Loza, Jordi Rodrigo.   

Abstract

BACKGROUND AND
PURPOSE: Human and rat 5-HT(7) receptors were studied with a particular emphasis on the molecular interactions involved in ligand binding, searching for an explanation to the interspecies selectivity observed for a set of compounds. We performed affinity studies, molecular modelling and site-directed mutagenesis, with special focus on residue Phe(7.38) of the human 5-HT(7) receptor [Cys(7.38) in rat]. EXPERIMENTAL APPROACH: Competition binding studies were performed for seven 5-HT(7) receptor ligands at three different 5-HT(7) receptors. The functional behaviour was evaluated by measuring 5-carboxytryptamine-stimulated cAMP production. Computational simulations were carried out to explore the structural bases in ligand binding observed for these compounds. KEY
RESULTS: Competition experiments showed a remarkable selectivity for the human receptor when compared with the rat receptor. These results indicate that mutating Cys to Phe at position 7.38 profoundly affects the binding affinities at the 5-HT(7) receptor. Computational simulations provide a structural interpretation for this key finding. Pharmacological characterization of compounds mr25020, mr25040 and mr25053 revealed a competitive antagonistic behaviour. Compounds mr22423, mr22433, mr23284 and mr25052 behaved as partial agonists. CONCLUSIONS AND IMPLICATIONS: We propose that the interspecies difference in binding affinities observed for the compounds at human and rat 5-HT(7) receptors is due to the nature of the residue at position 7.38. Our molecular modelling simulations suggest that Phe(7.38) in the human receptor is integrated in the hydrophobic pocket in the central part of the binding site [Phe(6.51)-Phe(6.52)] and allows a tighter binding of the ligands when compared with the rat receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922537      PMCID: PMC2839265          DOI: 10.1111/j.1476-5381.2009.00481.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  67 in total

1.  First pharmacophoric hypothesis for 5-HT7 antagonism.

Authors:  M L López-Rodríguez; E Porras; B Benhamú; J A Ramos; M J Morcillo; J L Lavandera
Journal:  Bioorg Med Chem Lett       Date:  2000-05-15       Impact factor: 2.823

2.  Packing optimization for automated generation of complex system's initial configurations for molecular dynamics and docking.

Authors:  José Mario Martínez; Leandro Martínez
Journal:  J Comput Chem       Date:  2003-05       Impact factor: 3.376

Review 3.  Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.

Authors:  Kurt Kristiansen
Journal:  Pharmacol Ther       Date:  2004-07       Impact factor: 12.310

4.  New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.

Authors:  José Brea; Jordi Rodrigo; Antonio Carrieri; Ferran Sanz; M Isabel Cadavid; María J Enguix; María Villazón; Guadalupe Mengod; Yolanda Caro; Christian F Masaguer; Enrique Raviña; Nuria B Centeno; Angelo Carotti; M Isabel Loza
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

5.  IsoStar: a library of information about nonbonded interactions.

Authors:  I J Bruno; J C Cole; J P Lommerse; R S Rowland; R Taylor; M L Verdonk
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

Review 6.  Molecular, pharmacological and functional diversity of 5-HT receptors.

Authors:  Daniel Hoyer; Jason P Hannon; Graeme R Martin
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

7.  A new method for predicting binding affinity in computer-aided drug design.

Authors:  J Aqvist; C Medina; J E Samuelsson
Journal:  Protein Eng       Date:  1994-03

8.  Generalization of a targeted library design protocol: application to 5-HT7 receptor ligands.

Authors:  Erik Nordling; Evert Homan
Journal:  J Chem Inf Comput Sci       Date:  2004 Nov-Dec

9.  Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects.

Authors:  A D Michel; W C Clay; S W Ng; S Roman; K Thompson; J P Condreay; M Hall; J Holbrook; D Livermore; S Senger
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

10.  SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats.

Authors:  David R Thomas; Sergio Melotto; Mario Massagrande; Andrew D Gribble; Phillip Jeffrey; Alexander J Stevens; Nigel J Deeks; Peter J Eddershaw; Susan H Fenwick; Graham Riley; Tania Stean; Claire M Scott; Matthew J Hill; Derek N Middlemiss; Jim J Hagan; Gary W Price; Ian T Forbes
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more
  3 in total

1.  Synthesis and structure evaluation of new complex butylarylpiperazin-1-yl derivatives.

Authors:  Daniel Szulczyk; Anna Bielenica; Michał A Dobrowolski; Lukasz Dobrzycki; Mariola Krawiecka; Bożena Kuran; Marta Struga
Journal:  Med Chem Res       Date:  2013-09-03       Impact factor: 1.965

2.  The arylpiperazine derivatives N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide and N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide exert a long-lasting inhibition of human serotonin 5-HT7 receptor binding and cAMP signaling.

Authors:  Patricio Atanes; Enza Lacivita; Javier Rodríguez; José Brea; Javier Burgueño; José Miguel Vela; María Isabel Cadavid; María Isabel Loza; Marcello Leopoldo; Marián Castro
Journal:  Pharmacol Res Perspect       Date:  2013-12-05

3.  Design and Synthesis of Arylpiperazine Serotonergic/Dopaminergic Ligands with Neuroprotective Properties.

Authors:  Margherita Mastromarino; Mauro Niso; Carmen Abate; Ewgenij Proschak; Mariam Dubiel; Holger Stark; Marián Castro; Enza Lacivita; Marcello Leopoldo
Journal:  Molecules       Date:  2022-02-15       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.